Kinnate Biopharma Inc.
NASDAQ:KNTE
2.65 (USD) • At close April 2, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.198 | 0.197 | 0.201 | 0.203 | 0.19 | 0.184 | 0.172 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.198 | -0.197 | -0.201 | -0.203 | -0.19 | -0.184 | -0.172 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 13.37 | 24.511 | 26.327 | 26.559 | 25.188 | 23.548 | 19.767 | 19.647 | 19.529 | 18.729 | 16.242 | 12.666 | 11.976 | 8.484 | 5.579 | 3.198 | 3.059 |
| General & Administrative Expenses
| 5.734 | 6.605 | 7.808 | 8.094 | 7.496 | 7.824 | 7.639 | 7.412 | 6.73 | 6.073 | 5.327 | 4.815 | 1.743 | 2.019 | 2.047 | 0.955 | 0.926 |
| Selling & Marketing Expenses
| -0.198 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.536 | 6.605 | 7.808 | 8.094 | 7.496 | 7.824 | 7.639 | 7.412 | 6.73 | 6.073 | 5.327 | 4.815 | 1.743 | 2.019 | 2.047 | 0.955 | 0.926 |
| Other Expenses
| 2.241 | 1.973 | 2.217 | 1.713 | 1.121 | 0.635 | 0.337 | 0.157 | 0 | -0.54 | -0.548 | -0.379 | 2.047 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 18.906 | 33.089 | 34.135 | 34.653 | 32.684 | 31.372 | 27.406 | 27.059 | 26.259 | 24.802 | 21.569 | 17.481 | 13.719 | 10.503 | 7.626 | 4.153 | 3.985 |
| Operating Income
| -19.104 | -33.089 | -34.135 | -34.653 | -32.684 | -31.372 | -27.406 | -27.059 | -26.259 | -24.802 | -21.569 | -17.481 | -13.719 | -10.503 | -7.626 | -4.153 | -3.985 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.046 | 2.356 | 2.217 | 1.713 | 1.121 | 0.635 | 0.337 | 0.157 | 0.1 | 0.1 | 0.124 | 0.024 | 0.012 | 0.004 | 0.012 | 0.212 | 0.043 |
| Income Before Tax
| -17.058 | -30.733 | -31.918 | -32.94 | -31.563 | -30.737 | -27.069 | -26.902 | -26.159 | -24.702 | -21.445 | -17.457 | -13.707 | -10.499 | -7.614 | -3.941 | -3.942 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0.197 | 0 | -1.713 | -1.615 | -0.635 | -0.337 | -0.157 | 0.012 | -0.64 | -0.672 | -0.403 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -17.058 | -30.733 | -31.918 | -31.227 | -29.948 | -30.102 | -26.732 | -26.745 | -26.159 | -24.702 | -21.445 | -17.457 | -13.707 | -10.499 | -7.614 | -3.941 | -3.942 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.36 | -0.65 | -0.68 | -0.69 | -0.68 | -0.68 | -0.61 | -0.61 | -0.6 | -0.57 | -0.49 | -0.4 | -0.31 | -0.26 | -0.33 | -0.17 | -0.091 |
| EPS Diluted
| -0.36 | -0.65 | -0.68 | -0.69 | -0.68 | -0.68 | -0.61 | -0.61 | -0.6 | -0.57 | -0.49 | -0.4 | -0.31 | -0.26 | -0.33 | -0.17 | -0.091 |
| EBITDA
| -18.906 | -33.089 | -33.934 | -34.45 | -32.494 | -31.188 | -27.234 | -27.001 | -26.223 | -24.774 | -21.541 | -17.45 | -13.695 | -10.48 | -7.606 | -4.137 | -3.985 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |